1-1 of 1
Federico Ambrogi
Close
Sort by
Journal Articles

First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis

Clinical Trials & Observations
Claudia Vener, Rita Banzi, Federico Ambrogi, Annalisa Ferrero, Giuseppe Saglio, Gabriella Pravettoni, Milena Sant
Journal: Blood Advances
Blood Adv (2020) 4 (12): 2723–2735.
https://doi.org/10.1182/bloodadvances.2019001329
Published: 2020
Includes: Supplemental data